The glucose transport protein, GLUT1, is highly expressed in rapidly proliferating cells, including cancer cells, while decreased GLUT1 levels are found in diseases such as GLUT1 deficiency syndrome and Alzheimer’s. There is increased interest in developing GLUT1 inhibitors as novel anticancer therapeutics, and the discovery of compounds that directly stimulate GLUT1 function. This work investigates how small molecules stimulate and/or inhibit GLUT1-mediated glucose transport, either directly or through the AMPK pathway. Using sugar transport assays and docking analyses to explore Ligand–GLUT1 interactions and specificity of binding, we show that: 1) Ligands inhibit GLUT1 by competing with glucose for binding to the exofacial or endofacial sugar binding sites; 2) Subsaturating inhibitor concentrations stimulate sugar uptake; 3) Ligands inhibit GLUT1–, GLUT3– and GLUT4–mediated sugar uptake in HEK293 cells; and 4) Inclusion of a benzonitrile head group on endofacial GLUT1 inhibitors confers greater inhibitory potency. Furthermore, we investigated AMPK-regulated GLUT1 trafficking in cultured blood-brain barrier endothelial cells, and show that inhibition of GLUT1 internalization is not responsible for increased cell surface levels of GLUT1 observed with AMPK activation in these cells. This study provides a framework for screening candidate GLUT1 inhibitors for specificity, and for optimizing drug design and delivery. Our data on transport stimulation at low inhibitor concentrations support the idea that GLUT1 functions as a cooperative oligomer of allosteric alternating access subunits.

<p>There has been a rapid shift in food environment of Western cultures that has increased consumption of diets high in fat and sugar, which have imparted negative effects on metabolic and neurocognitive health. There is also building evidence that the adverse effects of Western diet</p> <p>(WD) are different in males and females, such that males are impacted more at an earlier age and females are impacted later in life. The underlying biological mechanisms linking WD and neurocognitive health are often associated with energy dysregulation or neuroinflammation. WD</p> <p>disrupts glucose homeostasis and causes low grade inflammation in the body, and these can impact</p> <p>the brain by disrupting the blood-brain barrier (BBB). The BBB is the microvasculature found throughout the entire brain that tightly regulates what compounds get into the brain to ensure optimal neuronal function. WD disrupts the BBB, however, the effects of WD on BBB integrity</p> <p>in females and younger individuals remain largely unknown. Based on the metabolic and behavioral effects of WD, we hypothesized that the effects are age- and sex- specific. To test this, we gave male and female rats access to a WD for 8-10 weeks starting in juvenile period (post-natal</p> <p>day 21) or in adulthood (post-natal day 75), then measured body weight, behavior, glucose tolerance, the density of two different markers of BBB integrity. We also measured density of resident immune cells (microglia) to assess the relationship between inflammation and BBB integrity. First, we focused on the impact of hyperglycemia on the BBB since elevated glucose alters glucose transporter 1 (GLUT1). We found sex- and age- specific decreases in GLUT1 density in the prefrontal cortex and hippocampus—two brain regions commonly associated with neurocognitive impairments associated with WD. Correlational comparisons between WD and chow (CH) animals also found that the typically relationship between glucose tolerance and</p> <p>GLUT1 in the PFC and hippocampus were overall disrupted in WD animals. Second, we measured the leakage of albumin, a blood protein, since WD depletes the tight junctions that would typically prevent albumin from entering the brain and triggering a neuroinflammatory response. We did not find an increase in albumin density in WD animals, however, we found a main effect of age which</p> <p>offers insight to differential susceptibilities to BBB leakage. Third, we focused on inflammation and found that WD did not impact microglia density in our experiments, nor did it correlate with GLUT1, albumin, or behavior. Collectively, our findings support the hypothesis that the impact of</p> <p>WD on the BBB is sex- and age- specific, suggest that WD does not increase leakage of compounds such as albumin, and highlights the nuanced relationships between WD, metabolic disruption, behavioral deficits, and neuroinflammation.  </p>

L’acétyl-coA occupe une place centrale dans le métabolisme intermédiaire. Il constitue le point de jonction de plusieurs voies métaboliques telles que la .-oxydation, la glycolyse, le catabolisme de certains acides aminés, la cétolyse, la cétogenèse et la synthèse d’acides gras. Il est également impliqué dans d’autres processus tels que l’acétylation des protéines. Au cours de mon travail de thèse, je me suis attachée à étudier différents aspects du métabolisme de l’acétyl-coA. La première partie de mon travail a porté sur la modulation pharmacologique de la .- oxydation dans le but de corriger des déficits de cette voie métabolique. L’intérêt de traitements par 400µM de bézafibrate ou 75µM de resvératrol dans les formes modérées de déficit en VLCAD et en CPT2 avait été montré précédemment. Par des méthodes de référence et grâce à la mise au point de nouvelles techniques, j’ai pu montrer sur des fibroblastes de patients déficitaires en LCHAD que des traitements par une combinaison de 35µM de bézafibrate et 30µM de resvératrol permettent d’augmenter les capacités d’oxydation du palmitate en stimulant la synthèse protéique. L’effet de cette combinaison était comparable à celui d’un traitement par 400µM de bézafibrate. Dans un second temps, je me suis intéressée à deux cofacteurs impliqués dans le métabolisme de l’acétyl-coA : l’acide lipoïque, cofacteur de quatre .-cétoacides déshydrogénases (PDHc, BCKDHc, .- KGDHc et GCS) et la riboflavine, cofacteur d’acyl-coA déshydrogénases de la .-oxydation et de déshydrogénases impliquées dans le catabolisme des acides aminés ramifiés. Ainsi, j’ai participé à la description d’anomalies du métabolisme de l’acide lipoïque, un nouveau groupe de maladies héréditaires du métabolisme caractérisé par un déficit combiné en .-cétoacides déshydrogénases. Par ailleurs, j’ai pu montrer qu’une hyperprolinémie constitue un biomarqueur intéressant pour le diagnostic d’acidurie glutarique de type II primaire ou secondaire, ces dernières pouvant se rencontrer en cas d’anomalie du métabolisme de la riboflavine. J’ai également évalué l’utilisation d’un mélange racémique de L,D-3-hydroxybutyrate afin de corriger les déficits énergétiques induits par un déficit en PDHc ou GLUT1. Via la cétolyse, le L,D-3- hydroxybutyrate génère de l’acétyl-coA. De façon surprenante, l’administration de ce composé s’est traduite par une amélioration de l’état clinique des patients atteints de déficits en PDHc, alors qu’une dégradation a été observée chez les patients atteints de déficits en GLUT1. Cette évolution différente pourrait souligner l’importance de l’anaplérose chez les patients déficitaires en GLUT1. Enfin, la dernière partie de mon travail de thèse porte sur la description d’un patient atteint d’une forme modérée de déficit en pyruvate carboxylase, cette enzyme étant régulée par l’acétyl-coA. Les difficultés diagnostiques rencontrées devant ces formes modérées sont rapportées, ainsi que des essais de traitement par des composés anaplérotiques et par le bézafibrate, malheureusement sans bénéfice net que ce soit in vitro ou in vivo. En conclusion, le métabolisme de l’acétyl-coA est altéré dans de nombreuses maladies héréditaires du métabolisme, dont certaines sont de description récente. Il peut être modulé par différentes approches pharmacologiques. Le développement de nouvelles techniques et notamment les analyses de flux métaboliques fournissent des outils utiles à son exploration et à l’étude de nouveaux traitements. / Acetyl-CoA is crucial for intermediary metabolism. It is at the crossroad of several metabolic pathways such as beta-oxidation, glycolysis, aminoacid catabolism, ketolysis, and fatty acid synthesis. It is also involved in other processes such as protein acetylation. In this document I studied different aspects of acetyl-CoA metabolism. First, I tried to correct fatty acid oxidation defects through pharmacological approach. Thanks to well- known methods and new ones, I showed that a combination of 30µM resveratrol and 35µM bezafibrate increased fatty acid oxidation capacities by increasing protein synthesis, as well as 400µM bezafibrate. Acetyl-CoA metabolism is also altered due to cofactors defects such as lipoic acid or riboflavine deficiency. I was involved in new diseases description and research for new biomarkers in this context. PDHc and GLUT1 deficiency are two different diseases with the same consequence : a defect in acetyl- CoA production from glucose. In order to improve patients’ quality of life, I evaluated the substitution of ketogenic diet with a racemic mix of L,D-3-hydroxybutyrate in PDHc and GLUT1 deficiency. The clinical evolution of patients was strikingly different, with an improvement in PDHc patients, whereas a degradation was noticed in GLUT1 patients. This difference might underline the role of anaplerosis in GLUT1 deficiency. Finally, I evaluated anaplerotic treatment and bezafibrate treatment in pyruvate carboxylase deficiency, an enzyme allosterically regulated by acetyl-CoA. To conclude, acetyl-CoA metabolism is altered in numerous inherited errors of metabolism, some of them being recently described. It can be modulated by pharmacological approaches. The development of new techniques such as metabolic flux analysis are useful for its study and for new treatments evaluation.

Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation durchgeführt. Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und Laser-Scanning Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bildanalytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären cholinergen Innervation einhergeht. Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen.

Dans ce travail, nous démontrons que STIM1, un senseur calcique activé par la déplétion du Ca2+ intracellulaire du réticulum endoplasmique, est indispensable pour la signalisation calcique et la préférence oro-sensorielle du gras. Nous observons que l'acide linoléique (LA), en activant les phospholipases A2 via CD36, produit de l’acide arachidonique (AA) et de la lyso-phosphatidylcholine (lyso-PC). Cette activation déclenche un influx calcique dans les cellules CD36-positives, et induit la production du facteur CIF (Ca2+ Influx Factor). CIF, AA et lyso-PC exercent différentes actions sur l'ouverture des canaux SOC (Stored Operated Calcium Channel) constitués de protéines Orai et contrôlés par STIM1. Par ailleurs, les souris au phénotype Stim1-/- perdent la préférence spontanée pour les lipides et la libération de la sérotonine à partir des cellules gustatives dans le milieu extracellulaire chez les animaux sauvages. Nous demontrons aussi que la signalisation calcique médiée via CD36 est doublement modulée lors de l’obésité. L’augmentation de la [Ca2+]i dans les cellules gustatives observée chez le Psammomys obesus, un modèle d’obésité nutritionelle, est fortement diminuée chez les souris rendues obèses par un regime hyperlipidique. Nous avons constaté également que l’interaction de LA avec le CD36 induit l’activation des MAP Kinases de la voie MEK1/2/ERK1/2/Elk-1 qui est non seulement à l’origine de l’activation des aires cérébrales telles que le NTS, le noyau arqué, l’hippocampe mais aussi indispensable pour la préférence spontanée pour les lipides alimentaires. Nos résultats suggèrent pour la prémière fois, que la voie ERK1/2 des MAPK et la signalisation calcique lipidique controlée par STIM1 sont impliquées dans la perception oro-gustative des lipides / In this work, we demonstrate that stromal interaction molecule 1 (STIM1), a sensor of Ca2+ depletion in the endoplasmic reticulum, mediates fatty acid–induced Ca2+ signaling in the mouse tongue and fat preference. We showed that linoleic acid (LA) induced the production of arachidonic acid (AA) and lysophosphatidylcholine (Lyso-PC) by activating multiple phospholipase A2 isoforms via CD36. This activation triggered Ca2+ influx in lingual CD36-positive taste bud cells (TBCs) purified from mouse CVP. LA also induced the production of Ca2+ influx factor (CIF). STIM1 was found to regulate LA-induced CIF production and the opening of store-operated Ca2+ (SOC) channels. Furthermore, CD36-positive TBCs from Stim1–/– mice failed to release serotonin, and Stim1–/– mice lost the spontaneous preference for fat that was observed in wild-type animals. We also demonstrate that the calcium-mediated signaling via CD36 is doubly modulated in obesity. The increase in [Ca2+]i in taste bud cells observed in Psammomys obesus, a model of nutritional obesity is strongly reduced in diet-induced obese (DIO) mice. We also found that the interaction of LA with CD36 induces activation of MAP Kinases MEK1/2/ERK1/2/Elk-1 pathway that is not only responsible for the activation of NTS, arcuate nucleus, and the hippocampus in the brain but also essential for the spontaneous preference for fat food. Our results suggest for the first time, that ERK1/2 MAPK pathway and lipid-induced calcium signaling controlled by STIM1 are involved in oro-gustatory perception of dietary lipids

Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation durchgeführt. Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und Laser-Scanning Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bildanalytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären cholinergen Innervation einhergeht. Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen.:CHAPTER 1: INTRODUCTION 1.1 Alzheimer’s disease 1 1.2 APP processing and β-amyloid production 2 1.3 Cholinergic dysfunction in Alzheimer’s disease 5 1.4 Cerebrovascular abnormalities in Alzheimer’s disease 8 1.5 Cholinergic innervation of intracortical cerebral microvessels 9 1.6 Transgenic Tg2576 mouse model of Alzheimer’s disease 11 1.7 Aim of study 14 CHAPTER 2: MATERIALS AND METHODS 2.1 Materials 15 2.1.1 Chemical reagents used 15 2.1.2 Biological reagents used 15 2.1.3 Preparation of solutions and buffers 15 2.1.4 Antibodies and reagents used for immunohistochemistry 17 2.1.5 Transgenic animals 19 2.2 Methods 20 2.2.1 Tissue preparation and sampling of sections 20 2.2.2 Immunohistochemistry 20 2.2.2.1 Protocol of immunofluorescent labeling 20 2.2.2.2 Protocol of immunoperoxidase labeling (ABC technique) 21 2.2.2.3 Combination of primary and secondary antibodies 22 2.2.2.4 Protocol of β–amyloid immunolabeling (Formic acid epitope retrieval method) 23 2.2.3 Histochemistry 23 2.2.3.1 Thioflavin S staining 23 2.2.3.2 Nissl staining 23 2.2.3.3 Solanum Tuberosum Lectin (STL) staining 24 2.2.4 Double and triple-coloured immuno-/ histochemical staining of brain sections 24 2.2.5 Microscopy and digital image processing 25 2.2.6 Morphological and morphometric analyses 25 2.2.6.1 Cortical microvessels 25 2.2.6.2 Cortical cholinergic innervation 27 2.2.6.2.1 Total density of VAChT-immunoreactivity 27 2.2.6.2.2 Estimation of the density of varicosities on cholinergic fibres 29 2.2.6.3 Estimation of cholinergic perivascular innervation of cortical microvessels 29 2.2.6.4 Three-dimensional-imaging of vessels innervation 30 2.2.7 Statistical analysis 30 CHAPTER 3: RESULTS 3.1 Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice 31 3.1.1 Morphological distribution of brain vessels in the cerebral cortex of wild type mice 31 3.1.2 Microvessel density under plaque burden 33 3.2 Developmental and amyloid plaque-related changes in cholinergic neurotransmission in cholinoceptive target regions of transgenic Tg2576 mice 39 3.2.1 Visualisation of cholinergic nerve terminals in mouse brain 39 3.2.2 VAChT-Expression in wild type and transgenic Tg2576 mice 40 3.3 Role of cholinergic system in β-amyloid-related changes in the cerebrovascular system of transgenic Tg2576 mice 46 3.3.1 Solanum tuberosum lectin (STL) histochemistry in visualisation of brain vessels, β-amyloid, and microglia 46 3.3.1.1 Solanum tuberosum lectin and brain vessels 46 3.3.1.2 Solanum tuberosum lectin and β-amyloid plaques 47 3.3.1.3 Solanum tuberosum lectin staining to visualize glial cells 48 3.3.2 Cholinergic perivascular innervation of cerebral cortical microvessels in transgenic Tg2576 and wild type mice 50 CHAPTER 4: DISCUSSION 4.1 β-Amyloid and brain vascular system: the vascular hypothesis of Alzheimer’s disease 55 4.1.1 Evidences of a role of vascular mechanisms in Alzheimer’s disease 55 4.1.2 Effect of β-amyloid on brain vascular system 57 4.1.3 Effect of ischemia and hypoperfusion on APP processing 59 4.1.4 Effect of β-amyloid on cholinergic function in brain vascular system 59 4.2 Aim of study and main results obtained 61 4.3 Age-related changes in cerebral cortical microvessels in the presence and absence of β-amyloid plaque load 62 4.4 Age-related changes of cholinergic terminals in cholinoceptive target regions in the presence and absence of β-amyloid plaque load 64 4.4.1 VAChT – a reliable marker for detection of cholinergic terminals in cerebral cortex 64 4.4.2 The barrel field of the somatosensory cortex 1 (S1BF) as a model region to reveal age-related changes in cholinergic innervation 65 4.4.3 VAChT expression: morphological and morphometric studies 66 4.5 Age-related changes in cholinergic innervation of cerebral cortical microvessels in the presence and absence of β-amyloid plaque load 69 4.5.1 STL – a mono-marker for detection of cortical vessels, senile amyloid plaques and activated microglia in cerebral cortex 69 4.5.2 Cholinergic perivascular innervation of cerebral cortical microvessels in transgenic Tg2576 mice 70 4.5.3 Quantitation of cholinergic input on cerebral microvessels of mouse brain 71 4.6 Summary and conclusions 75 REFERENCES 77

<p>The human glucose transporter GLUT1 facilitates glucose to be accumulated on the other side of the cell membrane. The functional state of GLUT1 is uncertain due to diversity of the reports. In this thesis, the activity of red blood cell GLUT1 was extensively studied to further characterize this protein.</p><p>The human red blood cell membranes were stripped to become vesicles with low-ionic alkaline solution in the presence or absence of dithioerithritol. The supernatant of partially solubilized membrane vesicles provided approximately 65% of the vesicle proteins. GLUT1 purified from this supernatant showed a little high-affinity cytochalasin B binding activity. On the other hand, the vesicles stripped with dithioerythritol provided mostly monomeric GLUT1 and those without dithioerythritol provided monomeric and oligomeric GLUT1. MALDI-ToF-MS detected variant GLUT1 fragments between the two preparations. Residual endogenous phospholipids per GLUT1 also showed difference. However, the equilibrium exchange of glucose was retained for both GLUT1 preparations. Cytochalasin B-binding activity of GLUT1 in streptoavidin-biotin-immobilized red blood cells showed that both dissociation constant and binding sites per GLUT1 fell between those of wheat germ lectin-immobilized red blood cells with or without polylysine coating, which indicated the switching of two cytochalasin B-binding states of GLUT1. It is concluded that GLUT1 in red blood cells contains approximately two equal portions, monomeric with high-affinity cytochalasin B-binding activity and oligomeric without high-affinity cytochalasin B-binding activity. In the partial solubilization of the membrane vesicles, GLUT1 which does not have high-affinity cytochalasin B-binding activity is pooled. This might provide a resolution to select oligomerically and functionally different GLUT1 for crystallization.</p><p>In addition a modified micro-Bradford assay with CaPE precipitation was developed to achieve a routine quantitation method for membrane proteins and the effects of cholesterol and PEG(5000)-DSPE on reconstituted GLUT1 were preliminarily determined.</p>

The human glucose transporter GLUT1 facilitates glucose to be accumulated on the other side of the cell membrane. The functional state of GLUT1 is uncertain due to diversity of the reports. In this thesis, the activity of red blood cell GLUT1 was extensively studied to further characterize this protein. The human red blood cell membranes were stripped to become vesicles with low-ionic alkaline solution in the presence or absence of dithioerithritol. The supernatant of partially solubilized membrane vesicles provided approximately 65% of the vesicle proteins. GLUT1 purified from this supernatant showed a little high-affinity cytochalasin B binding activity. On the other hand, the vesicles stripped with dithioerythritol provided mostly monomeric GLUT1 and those without dithioerythritol provided monomeric and oligomeric GLUT1. MALDI-ToF-MS detected variant GLUT1 fragments between the two preparations. Residual endogenous phospholipids per GLUT1 also showed difference. However, the equilibrium exchange of glucose was retained for both GLUT1 preparations. Cytochalasin B-binding activity of GLUT1 in streptoavidin-biotin-immobilized red blood cells showed that both dissociation constant and binding sites per GLUT1 fell between those of wheat germ lectin-immobilized red blood cells with or without polylysine coating, which indicated the switching of two cytochalasin B-binding states of GLUT1. It is concluded that GLUT1 in red blood cells contains approximately two equal portions, monomeric with high-affinity cytochalasin B-binding activity and oligomeric without high-affinity cytochalasin B-binding activity. In the partial solubilization of the membrane vesicles, GLUT1 which does not have high-affinity cytochalasin B-binding activity is pooled. This might provide a resolution to select oligomerically and functionally different GLUT1 for crystallization. In addition a modified micro-Bradford assay with CaPE precipitation was developed to achieve a routine quantitation method for membrane proteins and the effects of cholesterol and PEG(5000)-DSPE on reconstituted GLUT1 were preliminarily determined.

Dans ce travail, nous démontrons que STIM1, un senseur calcique activé par la déplétion du Ca2+ intracellulaire du réticulum endoplasmique, est indispensable pour la signalisation calcique et la préférence oro-sensorielle du gras. Nous observons que l'acide linoléique (LA), en activant les phospholipases A2 via CD36, produit de l'acide arachidonique (AA) et de la lyso-phosphatidylcholine (lyso-PC). Cette activation déclenche un influx calcique dans les cellules CD36-positives, et induit la production du facteur CIF (Ca2+ Influx Factor). CIF, AA et lyso-PC exercent différentes actions sur l'ouverture des canaux SOC (Stored Operated Calcium Channel) constitués de protéines Orai et contrôlés par STIM1. Par ailleurs, les souris au phénotype Stim1-/- perdent la préférence spontanée pour les lipides et la libération de la sérotonine à partir des cellules gustatives dans le milieu extracellulaire chez les animaux sauvages. Nous demontrons aussi que la signalisation calcique médiée via CD36 est doublement modulée lors de l'obésité. L'augmentation de la [Ca2+]i dans les cellules gustatives observée chez le Psammomys obesus, un modèle d'obésité nutritionelle, est fortement diminuée chez les souris rendues obèses par un regime hyperlipidique. Nous avons constaté également que l'interaction de LA avec le CD36 induit l'activation des MAP Kinases de la voie MEK1/2/ERK1/2/Elk-1 qui est non seulement à l'origine de l'activation des aires cérébrales telles que le NTS, le noyau arqué, l'hippocampe mais aussi indispensable pour la préférence spontanée pour les lipides alimentaires. Nos résultats suggèrent pour la prémière fois, que la voie ERK1/2 des MAPK et la signalisation calcique lipidique controlée par STIM1 sont impliquées dans la perception oro-gustative des lipides

<p>Specific and non-specific interactions of solutes with immobilized biomembranes were studied using chromatographic methods. Liposomes, proteoliposomes and red blood cell (RBC) membrane vesicles were immobilized by a freeze-thawing procedure, whereas whole RBCs were adsorbed in the gel beds using electrostatic interaction, binding to wheat germ agglutinin (WGA) or the streptavidin-biotin interaction. </p><p>Superporous agarose gel with coupled WGA was the most promising matrix for RBC adsorption and allowed frontal chromatographic analyses of the cells for about one week. Dissociation constants for the binding of cytochalasin B and glucose to the glucose transporter GLUT1 were determined under equilibrium conditions. The number of cytochalasin B-binding sites per GLUT1 monomer was calculated and compared to corresponding results measured on free and immobilized membrane vesicles and GLUT1 proteoliposomes. This allowed conclusions about the protein´s binding state <i>in vitro</i> and <i>in vivo</i>. </p><p>Partitioning of drugs into biomembranes was quantified and the system was suggested as a screening method to test for possible intestinal absorption of drug candidates. We also studied how membrane partitioning of drugs is affected by the presence of integral membrane proteins or of charged phospholipids.</p><p>An attempt to combine the theory for specific binding and membrane partitioning of solutes in a single equation is briefly presented. </p>